NT-proBNP in Mitral Stenosis: Can It Be a Predictor of Hemodynamic Status?

Document Type : Original Article


1 Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.

2 Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.


Background: Mitral valve area (MVA) and other indices of the severity of mitral stenosis poorly reflect the functional status, systolic pulmonary artery pressure, and cardiac output in patients with severe mitral stenosis. In the present study, we aimed to compare the strength of conventional stenosis indices and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels in the prediction of major functional and hemodynamic consequences of mitral stenosis in a group of patients with a severe form of this disease.
Methods: Patients with severe symptomatic rheumatic mitral stenosis (MVA< 1.5 cm2) were enrolled. Comprehensive echocardiography and catheterization were performed for all the patients. MVA was measured via the 2D planimetry method, and NT-proBNP levels were measured during admission.
Results: Forty-one patients, 88% of whom were female, were enrolled in our study. The NT-proBNP level and MVA had a significantly negative correlation (ρ= −0.450 and P =0.003). The NT-proBNP level had a significant correlation with systolic pulmonary artery pressure (ρ= −0.423 and P = 0.006) and MV resistance (ρ= −0.506 and P = 0.001); however, the mean transmitral pressure gradient and the NT-proBNP level did not show a significant relationship. The strongest relationships were found between the NT-proBNP level and stroke volume and cardiac output, which were negatively significant (P = −0.601 and P = 0.000) and (ρ= −0.587 and P = 0.000), respectively.
Conclusions: It appears that the NT-proBNP level can be a good predictor of patients’ hemodynamic status such as cardiac output in addition to the echocardiographic features of mitral stenosis. (Iranian Heart Journal 2020; 21(3): 98-104)


  1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005 Nov; 5(11):685-94. DOI:10.1016/S1473-3099(05)70267-X
  2. Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med. 1994 Feb 1; 120(3):177-83.
  3. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009; 22(1):1-23; quiz 101-2.
    DOI: 10.1016/j.echo.2008.11.029
  4. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998 Jul 30;339(5):321-8.
    DOI: 10.1056/NEJM199807303390507
  5. Cheung BM, Kumana CR. Natriuretic peptides--relevance in cardiovascular disease. JAMA. 1998 Dec 16; 280(23):1983-4.
  6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Drazner MH, et al. American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.2013;62(16):e147–e239
    DOI: 10.1016/j.jacc.2013.05.019
  7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug; 18(8):891-975.
    DOI: 10.1002/ejhf.592
  8. Nakamura M, Kawata Y, Yoshida H, Arakawa N, Koeda T, Ichikawa T, et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J. 1992 Nov; 124(5):1283-8.
  9. Tharaux PL, Dussaule JC, Hubert-Brierre J, Vahanian A, Acar J, Ardaillou R. Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Clin Sci (Lond). 1994 Dec; 87(6):671-7.
  10. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998 Jan; 31(1):202-8.
  11. Iltumur K, Karabulut A, Yokus B, Yavuzkir M, Taskesen T, Toprak N. N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis. 2005 Nov; 14(6):735-41.
  12. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004 Mar 15; 6(3):289-93.
    DOI: 10.1016/j.ejheart.2003.12.012
  13. Faletra F, Pezzano A Jr, Fusco R, Mantero A, Corno R, Crivellaro W, et al. Measurement of mitral valve area in mitral stenosis: four echocardiographic methods compared with direct measurement of anatomic orifices. J Am Coll Cardiol. 1996 Nov 1; 28(5):1190-7.
    DOI: 10.1016/S0735-1097(96)00326-9
  14. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010 Mar; 51(2):151-63.
    DOI: 10.3349/ymj.2010.51.2.151
  15. ergler-Klein J, Gyöngyösi M, Maurer G. The role of biomarkers in valvular heart disease: focus on natriuretic peptides. Can J Cardiol. 2014 Sep; 30(9):1027-34.
    DOI: 10.1016/j.cjca.2014.07.014
  16. Arat-Ozkan A, Kaya A, Yigit Z, Balci H, Okçün B, Yazicioglu N, et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography. 2005 Jul; 22(6):473-8. DOI: 10.1111/j.1540-8175.2005.04085.x
  17. Sharma V, Stewart RA, Zeng I, Raffel C, Kerr AJ. Comparison of atrial and brain natriuretic peptide for the assessment of mitral stenosis. Heart Lung Circ. 2011 Aug; 20(8):517-24.
    DOI: 10.1016/j.hlc.2011.03.112
  18. Kilickesmez KO, Ozkan AA, Abaci O, Camlıca H, Kocas C, Kaya A, Baskurt M, Yiğit Z, Kucukoğlu S. Serum N-terminal brain natriuretic peptide indicates exercise induced augmentation of pulmonary artery pressure in patients with mitral stenosis. Echocardiography. 2011 Jan; 28(1):8-14. DOI: 10.1111/j.1540-8175.2010.01273.x
  19. Davutoglu V, Celik A, Aksoy M, Sezen Y, Soydinc S, Gunay N. Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease. Eur J Heart Fail. 2005 Jun; 7(4):532-6.
    DOI: 10.1016/j.ejheart.2004.07.006